FIELD: medicine; oncology.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for the treatment of WT1 (Wilms’ Tumor 1 protein) - positive multiple myeloma in a human patient. The method involves injecting a human patient with an allogeneic cell population containing WT1-specific allogeneic T cells, where the allogeneic cell population shows lysis of 20% or more of the antigen-presenting cells loaded with the WT1 peptide in an in vitro cytotoxicity assay, and where the allogeneic cell population is restricted by the HLA allele shared with the human patient. The group of inventions also relates to a method for WT1-positive plasma cell leukemia treatment.
EFFECT: use of this group of inventions secures antitumor activity of T-cell lines, causing WT1-specific T-cell responses associated with an increase in CD8+ and CD4+ WT1-specific T-cells in blood and bone marrow of these patients.
106 cl, 2 ex, 4 tbl, 6 dwg
